CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.More than half of patients who received zanidatamb (Jazz Pharmaceuticals/Zymeworks) monotherapy survived at least a year and median OS exceeded 15 months.
Related Keywords
Chicago ,Illinois ,United States ,Texas ,Bymark Leiser ,Mindy Valcarcel ,University Of Texas Md Anderson Cancer Center ,Jazz Pharmaceuticals Zymeworks ,Jazz Pharmaceuticals ,Shubham Pant ,Cancer Center ,
comparemela.com © 2020. All Rights Reserved.